Newly impaired glucose metabolism and prognosis after percutaneous revascularization

Jiménez-Navarro, Manuel F.; Fernández-Pastor, Julia; Garrido‐Sánchez, Lourdes; Molina-Mora, María J.; Ortiz-García, Carmen; Alonso‐Briales, Juan H.; Cabeza, Alejandro Isidoro Pérez; Hernández-García, José M.; Teresa–Galván, Eduardo de; Tinahones, Francisco J.

doi:10.5603/cj.a2014.0024

Cited by 4 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the 1,139 studies initially identified in the search, 17 studies 3,5,[10][11][12][13][14][15][16][17][18][19][20][21][22][23] (12 prospective and five retrospective) with 11,868 (76.5% male), 14,894 (78.5% male) and 13,536 (71.1% male) patients in the prediabetes, normoglycaemia and DM groups, respectively, were included in the final analysis. Seventeen studies compared outcomes for prediabetes versus normoglycaemia, while 12 studies compared outcomes for prediabetes versus DM at the longest follow-up.…”

Section: Resultsmentioning

confidence: 99%

Outcomes of Prediabetes Compared with Normoglycaemia and Diabetes Mellitus in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis

Ahsan,

Latif,

Ahmad

et al. 2023

Heart International

View full text Add to dashboard Cite

Background: Patients with prediabetes are at increased risk of coronary artery disease (CAD). However, the association between prediabetes and adverse clinical outcomes following percutaneous coronary intervention (PCI) is inconsistent, in contrast to outcomes in patients with diabetes mellitus (DM). Thus, this meta-analysis evaluated the impact of dysglycaemia on PCI outcomes. Methods: The PubMed, Embase, Cochrane, and ClinicalTrials. gov databases were systematically reviewed from inception of databases until June 2022. In 17 studies, outcomes of PCI in patients with prediabetes were compared with patients who were normoglycaemic, and patients with DM. The primary outcome was all-cause mortality at the longest follow-up. Results: Included were 12 prospective and five retrospective studies, with 11,868, 14,894 and 13,536 patients undergoing PCI in the prediabetes, normoglycaemic and DM groups, respectively. Normoglycaemic patients had a statistically lower risk of all-cause mortality, (risk ratio [RR] 0.66, 95% confidence interval [CI] 0.52–0.84), myocardial infarction (MI; RR 0.76, 95% CI 0.61–0.95) and cardiac mortality (RR 0.58, 95% CI 0.39–0.87) compared with prediabetic patients undergoing PCI at the longest follow-up. Patients with prediabetes had a lower risk of all-cause mortality (RR=0.72 [95% CI 0.53–0.97]) and cardiac mortality (RR =0.47 [95% CI 0.23–0.93]) compared with patients with DM who underwent PCI. Conclusion: Among patients who underwent PCI for CAD, the risk of all-cause and cardiac mortality, major adverse cardiovascular events and MI in prediabetic patients was higher compared with normoglycaemic patients but lower compared with patients with DM.

show abstract

Section: Resultsmentioning

confidence: 99%

Outcomes of Prediabetes Compared with Normoglycaemia and Diabetes Mellitus in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis

Ahsan,

Latif,

Ahmad

et al. 2023

Heart International

View full text Add to dashboard Cite

show abstract

“…IGT was shown to be a predictor of long-term CV risk, while previously known and newly diagnosed diabetes were not [ 44 ]. Contrarily, a study of 374 patients who underwent PCI reported that a known history of diabetes, but not newly diagnosed diabetes or IGT, was associated with revascularization, non-fatal MI, and readmission for HF after a mean follow-up of 35.8 months [ 45 ].…”

Section: Resultsmentioning

confidence: 99%

Emerging Biomarkers for Predicting Clinical Outcomes in Patients with Heart Disease

Pál

Bărcuțean

Lupu

et al. 2023

Life

View full text Add to dashboard Cite

Cardiovascular disease is most frequently caused by the development and progression of atherosclerosis. When coronary arteries are afflicted, and the stenoses caused by atherosclerotic plaques are severe enough, the metabolic supply-and-offer balance is disturbed, leading to myocardial ischemia. If atherosclerotic plaques become unstable and local thrombosis develops, a myocardial infarction occurs. Sometimes, myocardial ischemia and infarction may result in significant and irreversible heart failure. To prevent severe complications, such as acute coronary syndromes and ischemia-related heart failure, extensive efforts have been made for developing biomarkers that would help identify patients at increased risk for cardiovascular events. In this two-part study, we attempted to provide a review of existing knowledge of blood biomarkers that may be used in this setting. The first part of this work was dedicated to conventional biomarkers, which are already used in clinical practice. In the second part, here presented, we discuss emerging biomarkers which have not yet become mainstream.

show abstract

“…Subgroup analysis showed male and patients younger than 75 years appeared higher one-year MACCE risk. Jimenez-Navarro et al 13 discovered that 21.4% of 374 CAD patients who underwent PCI were newly detected diabetes and previously known diabetes remained the only independent predictor of cardiovascular events in a mean follow-up of 35.8 ± 13.43 months. Tsuchida et al 14 reported 17% of the 298 patients studied had newly diagnosed DM, which was not a predictor of up to 10-year cardiovascular disease risk.…”

Section: Discussionmentioning

confidence: 99%

Prevalence, clinical characteristics, and long-term outcomes of new diabetes diagnosis in elderly patients undergoing percutaneous coronary intervention

Xue,

Dai,

Ren

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Previous studies have reported associations between newly diagnosed diabetes and poor outcomes after percutaneous coronary intervention (PCI), but there is limited data focusing on elderly patients (age ≥ 65). This study aimed to analyze the prevalence and clinical implications of newly diagnosed diabetes in elderly patients who underwent PCI. From 2004 to 2021, a total of 2456 elderly patients who underwent invasive PCI at Korea University Guro Hospital were prospectively enrolled and followed up for a median of five years. The primary endpoint was five-year major adverse cardiovascular events (MACE). Cox regression was used to evaluate whether newly diagnosed diabetes impacted on long-term clinical outcomes. Newly diagnosed diabetes was presented in approximately 8.1% to 10.9% of elderly patients who underwent PCI. Those who had a new diagnosis of diabetes had a higher risk of MACE than previously known diabetes (25.28% vs. 19.15%, p = 0.039). After adjusting for significant factors, newly diagnosed diabetes remained an independent predictor of MACE (HR [hazard ratio] 1.64, 95% confidence interval [CI] 1.24–2.17, p < 0.001), cardiac death (HR 2.15, 95% CI 1.29–3.59, p = 0.003) and repeat revascularization (HR 1.52, 95% CI 1.09–2.11, p = 0.013), but not for non-fatal myocardial infarction (HR 1.66, 95% CI 0.94–2.12, p = 0.081). Newly diagnosed diabetes was associated with an increased risk of 5-year MACE compared with non-diabetes and previously diagnosed diabetes in elderly patients underwent PCI. More attention should be given to those elderly newly diagnosed diabetes population.

show abstract

Newly impaired glucose metabolism and prognosis after percutaneous revascularization

Cited by 4 publications

References 24 publications

Outcomes of Prediabetes Compared with Normoglycaemia and Diabetes Mellitus in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis

Outcomes of Prediabetes Compared with Normoglycaemia and Diabetes Mellitus in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis

Emerging Biomarkers for Predicting Clinical Outcomes in Patients with Heart Disease

Prevalence, clinical characteristics, and long-term outcomes of new diabetes diagnosis in elderly patients undergoing percutaneous coronary intervention

Contact Info

Product

Resources

About